علاج متلازمة QT الطويلة الخلقية — مريض بدون أعراض مع إطالة فترة QT

References

• Asymptomatic patient with or without pathogenic mutation and QT prolongation
• ICD implantation may be considered in asymptomatic LQTS patients with high-risk profile (according to the 1-2-3 LQTS Risk calculator) in addition to genotype-specific medical therapies (mexiletine in LQT3 patients).
• Avoid QT-prolonging drugs.
• Avoid and correct electrolyte abnormalities.
• Avoid genotype-specific triggers for arrhythmias.
• Beta-blockers, ideally non-selective beta-blockers (nadolol or propranolol), are recommended in LQTS patients with documented QT interval prolongation, to reduce risk of arrhythmic events.
• Mexiletine is indicated in LQT3 patients with a prolonged QT interval.
• It is advisable to perform oral testing to verify that the QTc shortens 40 ms before prescribing chronic treatment.